Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 301, Issue 6, 2011, Pages 1755-1764

  Mckay, Naomi J ^a   Kanoski, Scott E ^b   Hayes, Matthew R ^b,c   Daniels, Derek ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Exendin 4; Hypodipsia; Liraglutide; Thirst

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN FOURTH VENTRICLE; CENTRAL NERVOUS SYSTEM FUNCTION; CONTROLLED STUDY; DRUG EFFECT; FLUID INTAKE; FOOD INTAKE; FOREBRAIN; LATERAL BRAIN VENTRICLE; MAGNITUDE ESTIMATION METHOD; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RHOMBENCEPHALON; THIRST; TIME;

ANIMALS; DRINKING; EATING; GLUCAGON-LIKE PEPTIDE 1; MALE; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; TIME FACTORS; VENOMS;

EID: 82755164888     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00472.2011     Document Type: Article

References (47)

1. Barragan JM, Rodriguez RE, Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol Endocrinol Metab 266: E459-E466, 1994.
2. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8: 436-447, 2006.
3. Bojanowska E, Stempniak B. Effects of centrally or systemically injected glucagon-like peptide-1 (7-36) amide on release of neurohypophysial hormones and blood pressure in the rat. Regul Pept 91: 75-81, 2000.
4. Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 93: 3703-3716, 2008.
5. Christensen S. Effects of lithium on water intake and renal concentrating ability in rats with vasopressin-deficient diabetes insipidus (Brattleboro strain). Pflügers Arch 396: 106-109, 1983.
6. Ferry M. Strategies for ensuring good hydration in the elderly. Nutr Rev 63: S22-S29, 2005.
7. Fitzsimons TJ, Le Magnen J. Eating as a regulatory control of drinking in the rat. J Comp Physiol Psychol 67: 273-283, 1969.
8. Gardiner SM, March JE, Kemp PA, Bennett T. Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats. J Pharmacol Exp Ther 316: 852-859, 2006.
9. Gutzwiller JP, Hruz P, Huber AR, Hamel C, Zehnder C, Drewe J, Gutmann H, Stanga Z, Vogel D, Beglinger C. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion 73: 142-150, 2006.
10. Halbirk M, Norrelund H, Moller N, Holst JJ, Schmitz O, Nielsen R, Nielsen-Kudsk JE, Nielsen SS, Nielsen TT, Eiskjaer H, Botker HE, Wiggers H. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 298: H1096-H1102, 2010.
11. Hayes MR, De Jonghe BC, Kanoski SE. Role of the glucagon-likepeptide- 1 receptor in the control of energy balance. Physiol Behav 100: 503-510, 2010.
12. Hayes MR, Kanoski SE, Alhadeff AL, Grill HJ. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats. Obesity (Silver Spring) 19: 1342-1349, 2011.
13. Hayes MR, Leichner TM, Zhao S, Lee GS, Chowansky A, Zimmer D, De Jonghe BC, Kanoski SE, Grill HJ, Bence KK. Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation. Cell Metab 13: 320-330, 2011.
14. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 48: 612-615, 2005.
15. Isbil-Buyukcoskun N, Gulec G. Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin. Regul Pept 118: 33-38, 2004.
16. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin- 4. Endocrinology 152: 3103-3112, 2011.
17. Kinzig KP, D'Alessio DA, Seeley RJ. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci 22: 10470-10476, 2002.
18. Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, Bernard E, Benhamed F, Gremeaux T, Drucker DJ, Kahn CR, Girard J, Tanti JF, Delzenne NM, Postic C, Burcelin R. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 115: 3554-3563, 2005.
19. Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S. Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 38: 902-905, 1989.
20. Kristal MB, Steuer MA, Nishita JK, Peters LC. Neophobia and water intake after repeated pairings of novel flavors with toxicosis. Physiol Behav 24: 979-982, 1980.
21. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50: 2530-2539, 2001.
22. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77: 257-270, 1997.
23. Leech CA, Chepurny OG, Holz GG. Epac2-dependent rap1 activation and the control of islet insulin secretion by glucagon-like peptide-1. Vitam Horm 84: 279-302, 2010.
24. McMahon LR, Wellman PJ. PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am J Physiol Regul Integr Comp Physiol 274: R23-R29, 1998.
25. Meeran K, O'Shea D, Edwards CM, Turton MD, Heath MM, Gunn I, Abusnana S, Rossi M, Small CJ, Goldstone AP, Taylor GM, Sunter D, Steere J, Choi SJ, Ghatei MA, Bloom SR. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9 -39) alters body weight in the rat. Endocrinology 140: 244-250, 1999.
26. Meier JJ, Gallwitz B, Schmidt WE, Nauck MA. Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 440: 269-279, 2002.
27. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403: 261-280, 1999.
28. Mojsov S, Kopczynski MG, Habener JF. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem 265: 8001-8008, 1990.
29. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 124: S3-S18, 2011.
30. Navarro M, Rodriquez de Fonseca F, Alvarez E, Chowen JA, Zueco JA, Gomez R, Eng J, Blazquez E. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 67: 1982-1991, 1996.
31. Norgren R, Leonard CM. Ascending central gustatory pathways. J Comp Neurol 150: 217-237, 1973.
32. Rinaman L. Ascending projections from the caudal visceral nucleus of the solitary tract to brain regions involved in food intake and energy expenditure. Brain Res 1350: 18-34, 2010.
33. Robinson MM, Evered MD. Pressor action of intravenous angiotensin II reduces drinking response in rats. Am J Physiol Regul Integr Comp Physiol 252: R754-R759, 1987.
34. Ruttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 150: 1174-1181, 2009.
35. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 57: 2046-2054, 2008.
36. Scott KA, Moran TH. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am J Physiol Regul Integr Comp Physiol 293: R983-R987, 2007.
37. Seeley RJ, Blake K, Rushing PA, Benoit S, Eng J, Woods SC, D'Alessio D. The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci 20: 1616-1621, 2000.
38. Smith DF, Amdisen A. Central effects of lithium in rats: lithium levels, body weight and water intake. Acta Pharmacol Toxicol (Copenh) 52: 81-85, 1983.
39. Spitz R. Induction of drinking by insulin in the rat. Eur J Pharmacol 31: 110-114, 1975.
40. Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M, Sheikh SP. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol Regul Integr Comp Physiol 271: R848-R856, 1996.
41. Thiele TE, Seeley RJ, D'Alessio D, Eng J, Bernstein IL, Woods SC, van Dijk G. Central infusion of glucagon-like peptide-1-(7-36) amide (GLP-1) receptor antagonist attenuates lithium chloride-induced c-Fos induction in rat brainstem. Brain Res 801: 164-170, 1998.
42. Thiele TE, Van Dijk G, Campfield LA, Smith FJ, Burn P, Woods SC, Bernstein IL, Seeley RJ. Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am J Physiol Regul Integr Comp Physiol 272: R726-R730, 1997.
43. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72, 1996.
44. van Dijk G, Thiele TE, Seeley RJ, Woods SC, Bernstein IL. Glucagonlike peptide-1 and satiety. Nature 385: 214, 1997.
45. Wang T, Edwards GL, Baile CA. Glucagon-like peptide-1 (7-36) amide administered into the third cerebroventricle inhibits water intake in rats. Proc Soc Exp Biol Med 219: 85-91, 1998.
46. Williams DL, Baskin DG, Schwartz MW. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 150: 1680-1687, 2009.
47. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110: 43-52, 2002.